Osteoarthritis and Bone Disorders News

A new blood test may offer a more accurate way to track and predict the progression of knee osteoarthritis than current approaches, according to a press release from Duke Health.

Women with osteoporosis receiving abaloparatide for 18 months followed by alendronate for 2 years had greater improvements in trabecular bone score than those receiving placebo, according to study findings.

Patients with knee osteoarthritis and self-reported knee instability benefit more from education and supervised exercise compared with those without instability, according to data published in Arthritis Care & Research.

Despite similar outcomes following endovascular thrombectomy anterior large vessel ischemic stroke, patients with osteoarthritis were 22.5% less likely to undergo EVT compared with those without it, researchers reported.

Solutions for halting osteoarthritis progression and avoiding need for joint replacement remain elusive, but new therapy options, including a novel injection, made headlines in 2022.

Bone size and trabecular disorganization appear to increase with osteophyte formation and joint space narrowing, while volumetric bone mineral density decreases, according to data published in Arthritis Research & Therapy.

The FDA has approved abaloparatide, a parathyroid hormone-related peptide analog, to increase bone mineral density among men with osteoporosis at high risk for fracture, according to an industry press release.

Osteoporosis remains highly prevalent among patients with rheumatoid arthritis despite advancements in prevention and treatment, according to data published in Scientific Reports.

Compared with online education alone, unsupervised online yoga courses can provide short-term benefits to physical function, but not knee pain, in osteoarthritis, according to data published in the Annals of Internal Medicine.

Repeat injections of the Wnt pathway inhibitor lorecivivint appears to have slowed the decline of medial joint space width in knee osteoarthritis, according to interim results from a long-term extension trial released by Biosplice.